Iovance Biotherapeutics I... (IOVA)
3.21
0.13 (4.22%)
At close: Apr 22, 2025, 3:59 PM
3.31
3.28%
Pre-market: Apr 23, 2025, 06:09 AM EDT
Iovance Biotherapeutics Revenue Breakdown
| Period Ending | Sep 30, 2023 | Jun 30, 2023 |
|---|---|---|
| Product Revenue | 500K | 200K |
| Product Revenue Growth | +150.00% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2023 |
|---|---|
| Non-Us Revenue | 1.2M |
| Non-Us Revenue Growth | n/a |
| United States Revenue | n/a |
| United States Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 39.55M | 34.19M | 26.12M | 20.19M | 26.96M | 21.93M | 28.12M | 26.46M | 27.89M | 26.33M | 23.41M | 23.85M | 20.89M | 19.31M | 19.62M | 16.08M | 15.92M | 14.35M | 13.86M | 10.87M | 10.03M | 10.87M | 9.08M | 7.53M | 7.11M | 6.83M | 6.96M | 5.38M | 4.59M | 3.93M | 4.26M | 5.02M | 10.5M | 7.26M | 2.82M | 3.93M | 2.66M | 2.38M | 3.29M |
| Selling, General, and Administrative Revenue Growth | +15.69% | +30.90% | +29.37% | -25.13% | +22.97% | -22.03% | +6.27% | -5.13% | +5.94% | +12.45% | -1.83% | +14.18% | +8.18% | -1.60% | +22.00% | +1.05% | +10.89% | +3.57% | +27.47% | +8.41% | -7.71% | +19.67% | +20.68% | +5.79% | +4.19% | -1.98% | +29.58% | +17.10% | +16.85% | -7.77% | -15.19% | -52.16% | +44.52% | +157.77% | -28.24% | +47.63% | +11.55% | -27.46% | n/a |
| Research and Development Revenue | 68.25M | 62.08M | 79.78M | 87.47M | 87.53M | 86.35M | 82.73M | 80.57M | 72.5M | 73.41M | 68.3M | 75.62M | 65.36M | 62.12M | 55.95M | 52.45M | 43.05M | 49.27M | 56.95M | 54.24M | 41.58M | 39.3M | 30.91M | 27.42M | 27.95M | 24.55M | 19.91M | 20.7M | 17.75M | 19.65M | 16.62M | 10.9M | 8.48M | 4.46M | 4.19M | 5.11M | 4.98M | 4.06M | 2.01M |
| Research and Development Revenue Growth | +9.92% | -22.18% | -8.79% | -0.06% | +1.37% | +4.37% | +2.68% | +11.13% | -1.23% | +7.48% | -9.68% | +15.70% | +5.21% | +11.03% | +6.67% | +21.84% | -12.63% | -13.48% | +5.00% | +30.44% | +5.81% | +27.16% | +12.72% | -1.89% | +13.83% | +23.30% | -3.79% | +16.58% | -9.67% | +18.23% | +52.49% | +28.53% | +90.03% | +6.46% | -17.92% | +2.49% | +22.86% | +101.67% | n/a |